Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 44,400 shares, a growth of 88.9% from the May 30th total of 23,500 shares. Currently, 1.9% of the company’s shares are short sold. Based on an average daily volume of 10,800 shares, the days-to-cover ratio is currently 4.1 days.
Shares of Entasis Therapeutics stock traded up $0.02 during midday trading on Thursday, reaching $6.35. 1,300 shares of the company’s stock traded hands, compared to its average volume of 10,540. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.79 and a current ratio of 8.79. The company has a market capitalization of $83.91 million and a P/E ratio of -0.52. The company’s 50 day moving average is $6.24. Entasis Therapeutics has a 12 month low of $3.97 and a 12 month high of $13.70.
Entasis Therapeutics (NASDAQ:ETTX) last announced its earnings results on Tuesday, May 14th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.24). Research analysts anticipate that Entasis Therapeutics will post -3.39 EPS for the current year.
ETTX has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $19.00 price objective on shares of Entasis Therapeutics in a research report on Tuesday, April 2nd. Zacks Investment Research downgraded GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a research report on Monday, May 20th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Entasis Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $16.50.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Read More: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.